Exelixis
EXEL
#1574
Rank
โ‚น946.92 B
Marketcap
โ‚น3,383
Share price
2.76%
Change (1 day)
86.25%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Earnings for Exelixis (EXEL)

Earnings in 2024 (TTM): โ‚น57.32 Billion

According to Exelixis's latest financial reports the company's current earnings are โ‚น2.16 Billion. , an increase over its 2023 earnings that were of โ‚น22.51 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Exelixis from 2000 to 2024

Annual earnings

Year Earnings Change
2024 โ‚น59.60 B164.69%
2023 โ‚น22.51 B9.89%
2022 โ‚น20.49 B-20.33%
2021 โ‚น25.72 B124.82%
2020 โ‚น11.44 B-67.14%
2019 โ‚น34.81 B-11.94%
2018 โ‚น39.53 B185.09%
2017 โ‚น13.86 B-325.82%
2016 -โ‚น6.15 Billion-58.12%
2015 -โ‚น14.67 Billion-37.61%
2014 -โ‚น23.5 Billion9.75%
2013 -โ‚น21.42 Billion65.96%
2012 -โ‚น12.91 Billion-291.63%
2011 โ‚น6.73 B-195.59%
2010 -โ‚น7.05 Billion-42.17%
2009 -โ‚น12.18 Billion-18.98%
2008 -โ‚น15.04 Billion-6.99%
2007 -โ‚น16.17 Billion46.3%
2006 -โ‚น11.05 Billion33.25%
2005 -โ‚น8.3 Billion-30.92%
2004 -โ‚น12.01 Billion44.29%
2003 -โ‚น8.32 Billion12.86%
2002 -โ‚น7.38 Billion22.79%
2001 -โ‚น6.01 Billion60.14%
2000 -โ‚น3.75 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
โ‚น364.73 B 511.89%๐Ÿ‡ฌ๐Ÿ‡ง UK
โ‚น694.50 B 1,065.14%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚น1.309 T 2,096.61%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น732.72 Billion-1,329.24%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น403.04 B 576.16%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น1.525 T 2,458.83%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น607.14 B 918.57%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น3.92 Billion-106.57%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น2.54 Billion-104.26%๐Ÿ‡บ๐Ÿ‡ธ USA